Dosage aerosols for the application of pharmaceutical formulations

US9937306B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9937306-B2
Application numberUS-201113020200-A
CountryUS
Kind codeB2
Filing dateFeb 3, 2011
Priority dateMar 27, 2006
Publication dateApr 10, 2018
Grant dateApr 10, 2018

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The invention relates to pharmaceutical active substances, active substance mixtures and formulations for use as an aerosol in propellant-containing [1.1.1.2-tetrafluoroethane (HFC-134a) or 1.1.1.2.3.3.3-heptafluoropropane(HFC-227)] metered-dose aerosols and the metered-dose aerosols for administering these active substances, active substance mixtures and formulations.

First claim

Opening claim text (preview).

What is claimed is: 1. A device for providing pharmaceutical active substances, active substance mixtures, and formulations, comprising: a container having a valve stem extending along an axis, the container being filled with a pharmaceutical preparation, containing an active substance, an active substance mixture or formulation in pressure-liquefied 1.1.1.2-tetrafluoroethane (HFC-134a) or 1.1.1.2.3.3.3-heptafluoropropane (HFC-227) or a mixture of HFC-134a and HFC-227, a shaft within which the container is disposed, a valve stem receptacle receiving at least a portion of the valve stem of the container and having a channel extending away from the valve stem about the axis and tapering to a channel opening at a terminus of the channel such that a volume of the channel terminates at the channel opening and no volume of the channel exists along the axis beyond the channel opening, where the tapering is characterised by: (i) respective decreasing radial distances taken perpendicularly from the axis to a surface of the channel as the radial distances are taken along the axis at positions farther from the valve stem, and (ii) respective substantially constant radial distances taken perpendicularly from the axis to the surface of the channel when the radial distance is in a common plane with the axis and the channel opening, and a nozzle bore extending into the valve stem receptacle transversely to the channel such that: (i) the nozzle bore impacts upon the channel at an obtuse angle to the axis extending from the valve stem, and (ii) the pharmaceutical composition, mixture or formulation which is liquefied under pressure is directed at greater than 90 degrees from a direction along the axis from the valve stem and outwards through the nozzle bore, thereby generating a spray cloud at a transition from the nozzle bore to a nozzle opening. 2. The device according to claim 1 , wherein a diameter of the channel proximate to the valve stem corresponds approximately to an internal diameter of the valve stem. 3. The device according to claim 1 , wherein the pharmaceutical preparation additionally contains suspension adjuvants, surfactants and/or stabilisers. 4. The device according to claim 1 , wherein the channel is connected, via the nozzle bore, to the nozzle opening which is of funnel-shaped construction. 5. The device according to claim 1 , wherein the pharmaceutical preparation contains an anticholinergic or a betamimetic or a steroid or a phosphodiesterase-IV-inhibitor or a LTD4-antagonist and EGFR-kinase inhibitor or a antiallergic agent or a ergot alkaloid derivative or triptan or a CGRP-antagonist or a phosphodiesterase-V-inhibitor, or combinations of such active substances. 6. The device of claim 1 , wherein the valve stem has an internal diameter between 1.68 mm to 2.12 mm. 7. The device of claim 1 , wherein a width of the channel at the terminus thereof is constricted to approximately a diameter of the nozzle bore. 8. The device of claim 7 , wherein the nozzle bore has a diameter of between 0.2-0.6 mm.

Assignees

Inventors

Classifications

  • A61M15/009Primary

    using medicine packages with incorporated spraying means, e.g. aerosol cans (pocket atomiser of the injector type A61M11/08) · CPC title

  • characterised by details or accessories associated with outlets · CPC title

  • for aerosols (aerosol containers B65D83/14) · CPC title

  • Gas or vapour producing the flow, e.g. from a compressible bulb or air pump · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9937306B2 cover?
The invention relates to pharmaceutical active substances, active substance mixtures and formulations for use as an aerosol in propellant-containing [1.1.1.2-tetrafluoroethane (HFC-134a) or 1.1.1.2.3.3.3-heptafluoropropane(HFC-227)] metered-dose aerosols and the metered-dose aerosols for administering these active substances, active substance mixtures and formulations.
Who is the assignee on this patent?
Wachtel Herbert, Hoelz Hubert, Rohrschneider Marc, and 1 more
What technology area does this patent fall under?
Primary CPC classification A61M15/009. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Tue Apr 10 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).